Part of the Stock Digest group of websites: Visit Small Cap Stock Digest  

Ellis Martin Report with Lexagene's Dr Jack Regan

Ellis Martin Report with Lexagene's Dr Jack Regan

Join Ellis Martin for an interview with Dr Jack Regan, the CEO and founder of Lexagene (TSX-V:LXG/OTCQB: LXXGF). 

LexaGene is a biotechnology company developing a fully automated pathogen detection platform for use at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. LexaGene’s technology aims to transform the way organizations prevent and diagnose disease in multi-billion dollar markets such as food safety, veterinary diagnostics, water quality monitoring, aquaculture pathogen surveillance, and more. LexaGene’s patented microfluidic system was invented by company founder and CEO, Dr. Jack Regan, who was a lead scientist in developing a predecessor instrument designed for bio-warfare surveillance that was adopted by the Department of Homeland Security for the BioWatch Program and a second R&D instrument that was designed for detecting respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20M in government funding. LexaGene’s experienced leadership team is driving company growth with a focus on innovation, pursuing unique market opportunities, and providing shareholder value.

Subscribe to the SCSD email list and get the latest small cap stock activity directly to your inbox, for free.

MARKET SUMMARY

INDICES

Name Last Change
DOW 25444.30 0.26%
S&P 500 2767.78 0.04%
NASDAQ 7449.03 0.48%
TSX 15470.10 0.43%
TSX-V 682.16 0.00%
RTY 1542.04 1.21%

Technology

Name Last Change
APPL 219.31 1.50%
GOOG 1096.46 0.77%

@SmallCapDigest ON TWITTER

Part of the Stock Digest family of websites
Resource Stock Digest